An approach using engineered small extracellular vesicles from NK cells to DR5 could be a promising strategy for solid tumors ...

Our scientists should be proceeding with extreme caution, but unfortunately for us, that simply isn’t happening.

Cory Berkland delivers an address at his installation ceremony as the Mark and Becky Ruhmann Levin Professor in the McKelvey ...

Cell BioEngines Joins Center for Engineering and Precision Medicine (CEPM), Expands Relationship with Mount SinaiNEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- (“Cell BioEngines” or the “Company”), a ...

The confirmatory IGNYTE-3 trial is assessing RP1 in combination with nivolumab in patients with advanced melanoma who have progressed on anti-PD-1 and anti-CTLA-4 therapies or are ineligible for ...